Clinical Trials Sponsored by Panthera Dental Inc.

Total 456 results

Panthera Dental Inc.
AXONAL

Recruiting

Long-term Efficacy, Tolerance and Compliance of Panthera D-SAD® Mandibular Advancement Orthosis in Sleep Apnea (PANTHERA)

Sleep Apnea, Obstructive

France
Xenthera, Inc.

Not yet recruiting

Subjects With Advanced or Metastatic Solid Tumor Malignancies

Advanced Solid Tumor | Metastatic Solid Tumor
PanTheryx, Inc.

Completed

Study With Medical Nutrition Product PTM202 in Pediatric Diarrhea

Acute Diarrhea

Bangladesh
ProThera, Inc.

Unknown

Efficacy of Myalgesin™ to Support Joint Function in Patients With Knee Osteoarthritis

Osteoarthritis

United States
ReveraGen BioPharma, Inc.
Santhera Pharmaceuticals

Recruiting

A Study to Assess Vamorolone in Becker Muscular Dystrophy (BMD)

Becker Muscular Dystrophy

United States, Italy
NIZO Food Research
PanTheryx, Inc.

Completed

PTM202 and Modulation of Host Resistance to Diarrheagenic E. Coli (APA12/PANTER)

Traveler's Diarrhea

Netherlands
Northwestern University
Agenus Inc.; CarThera

Recruiting

Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma

Glioblastoma Multiforme | Gliosarcoma | Newly Diagnosed Glioblastoma | Glioblastoma, Isocitric Dehydrogenase (IDH)-Wildtype

United States
Venthera, Inc., a BridgeBio company

Terminated

First in Human Trial of Topical VT30 in Pts With Venous/Lymphatic Malformations Assoc With PIK3CA or TEK Gene Mutations

Lymphatic Malformation | Venous Malformation | Venolymphatic Malformation

United States
University of Colorado, Denver
PanTheryx, Inc.

Completed

Impact of the Nutritional Product PTM202 on Acute and Long-Term Recovery From Childhood Diarrheal Disease

Diarrhea

Guatemala
Indiana University
Delta Dental Foundation; Water Pik, Inc.

Completed

Evaluation of Oral Plaque Removal Utilizing an Adjunct Enzyme Pre-rinse

Dental Caries | Dental Plaque

United States
Fenwal, Inc.

Not yet recruiting

Evaluation of the Aurora Xi New Nomogram Software 2.0

Apheresis Related Hypotension

United States
Fenwal, Inc.

Completed

Evaluation of Therapeutic Plasma Exchange (TPE) Procedure Using the AMICUS Device

Autoimmune Diseases | Oncologic Disorders | Renal Disorders | Hematologic Disorders

United States
National Dental Centre, Singapore
Sunstar, Inc.

Unknown

Assessment of the Accuracy of the Clinical Parameters & Radiographs in Determining the Topography of Implant Bony Lesions

Peri-Implantitis

Singapore
Denali Therapeutics Inc.

Recruiting

A Study to Determine the Efficacy and Safety of Tividenofusp Alfa (DNL310) vs Idursulfase in Pediatric Participants With Neuronopathic (nMPS II) or Non-Neuronopathic Mucopolysaccharidosis Type II (nnMPS II) (COMPASS)

Mucopolysaccharidosis II

United States, Spain, United Kingdom, Czechia, France, Canada, Italy, Belgium, Netherlands, Germany, Argentina, Sweden, Turkey, Colombia, Brazil
Denali Therapeutics Inc.

Active, not recruiting

A Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of DNL343 in Participants With Amyotrophic Lateral Sclerosis

Amyotrophic Lateral Sclerosis

United States, Netherlands
Denali Therapeutics Inc.

Completed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL343 in Healthy Volunteers

Healthy Volunteers

Netherlands
Denali Therapeutics Inc.

Completed

Study to Evaluate DNL201 in Subjects With Parkinson's Disease

Parkinson Disease

United States
Denali Therapeutics Inc.

Recruiting

A Phase 1, Open-label Study of the Absorption, Metabolism, and Excretion of [14C]-DNL343 Following a Single Oral Dose in Healthy Male Participants

Healthy Volunteers

United States
Denali Therapeutics Inc.

Active, not recruiting

A Study of Tividenofusp Alfa (DNL310) in Pediatric Participants With Hunter Syndrome

Mucopolysaccharidosis II

United States, Netherlands, Canada, United Kingdom
Denali Therapeutics Inc.

Enrolling by invitation

An Extension Study of the Long-Term Safety, Tolerability, and Efficacy of Tividenofusp Alfa (DNL310) in Participants With Mucopolysaccharidosis Type II (MPS II) From Study DNLI-E-0002 or Study DNLI-E-0007

Mucopolysaccharidosis II

United States, Canada, Belgium, Czechia, Netherlands
Denali Therapeutics Inc.

Completed

Study to Evaluate DNL747 in Subjects With Alzheimer's Disease

Alzheimer Disease

United States, Netherlands
Central FITT, Inc

Unknown

Research Study of Nutritional Methods to Reduce Body Fat Percentages in Overweight and Obese Populations

Obesity

United States
Denali Therapeutics Inc.

Recruiting

Study of DNL126 in Pediatric Participants With Mucopolysaccharidosis Type IIIA (Sanfilippo Syndrome Type A)

Mucopolysaccharidosis Type IIIA

United States
Denali Therapeutics Inc.

Completed

A Study of Potential Treatment-Responsive Biomarkers and Clinical Outcomes in Hunter Syndrome

Mucopolysaccharidosis II

United Kingdom, United States, Italy, Netherlands
Denali Therapeutics Inc.

Completed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL151 in Healthy Volunteers

Healthy Volunteers

Netherlands
Denali Therapeutics Inc.

Completed

A Study to Evaluate the Bioavailability and Safety of DNL343 in Healthy Volunteers

Healthy Volunteers

New Zealand
Denali Therapeutics Inc.

Completed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL201 in Healthy Volunteers

Healthy Volunteers

United States
Entac Medical Inc.

Recruiting

Evaluation of the PrevisEA Device for Predicting Gastrointestinal Impairment

Gastrointestinal Complication

United States
Denali Therapeutics Inc.
Takeda

Active, not recruiting

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL593 in Healthy Participants and Participants With Frontotemporal Dementia (FTD-GRN)

Frontotemporal Dementia

Spain, Turkey, France, Belgium, Netherlands, Portugal, Italy, Colombia, Czechia, Brazil, United Kingdom, Serbia
Sanofi
Denali Therapeutics Inc.

Terminated

Study to Evaluate DNL747 in Subjects With Amyotrophic Lateral Sclerosis

Amyotrophic Lateral Sclerosis

United States, Netherlands
Denali Therapeutics Inc.
Takeda

Completed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL919 in Healthy Participants

Healthy Participant

Netherlands
Biogen
Denali Therapeutics Inc.

Completed

A Study to Determine the Absolute Bioavailability of BIIB122/DNL151 in Healthy Subjects

Healthy Volunteers

United States
Biogen
Denali Therapeutics Inc.

Recruiting

A Study to Assess the Safety of BIIB122 Tablets and if it Can Slow the Worsening of Early-Stage Parkinson's Disease in Participants Between the Ages of 30 and 80 (LUMA)

Parkinson Disease

United States, Netherlands, Italy, Spain, Israel, Canada, China, Germany, France, Austria, United Kingdom, Poland, Japan
Biogen
Denali Therapeutics Inc.

Terminated

A Study to Assess if BIIB122 Tablets Are Safe and Can Slow Worsening of Early-Stage Parkinson's Disease in Participants With Specific LRRK2 Genetic Variants Between the Ages of 30 and 80 Using the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (LIGHTHOUSE)

Parkinson Disease

United States, Italy, Spain, Germany, France, United Kingdom
Biogen
Denali Therapeutics Inc.

Completed

A Study of Mass Balance, Pharmacokinetics, Metabolite Profile, and Metabolite Identification of BIIB122/DNL151 in Healthy Male Subjects

Healthy Volunteers

United States
Research Foundation for Mental Hygiene, Inc.

Terminated

Meditation and Stretching for Post Treatment Lyme Disease Syndrome (LMS)

Post Treatment Lyme Disease Syndrome

United States
Research Foundation for Mental Hygiene, Inc.

Completed

The COVID-19 and Healthcare Workers: An Active Intervention

Brief Video-based Intervention | Non Intervention Control

United States
Research Foundation for Mental Hygiene, Inc.

Withdrawn

Meditation and Kundalini Yoga for Persistent Lyme-related Symptoms - an Online Study

Post-Treatment Lyme Disease
Research Foundation for Mental Hygiene, Inc.

Completed

Addressing COVID-19 Mental Health Problems Among US Veterans

Brief Video-based Intervention | Vignette Based Intervention | Non Intervention Control Arm

United States
Research Foundation for Mental Hygiene, Inc.

Completed

Reducing Alcohol Dependence Among HIV-Positive Individuals

Alcohol Dependence
Research Foundation for Mental Hygiene, Inc.

Unknown

Medication and Counseling for Controlled Drinking (ProjectSMART)

Alcohol Dependence | Alcohol Abuse

United States
Research Foundation for Mental Hygiene, Inc.

Completed

Attention-Bias Modification Treatment for PTSD

Posttraumatic Stress Disorder (PTSD)

United States
Research Foundation for Mental Hygiene, Inc.

Completed

HealthCall:Brief Intervention to Reduce Non-injecting Drug Use in HIV Primary Care Clinics

Mental and Behavioral Disorders Due to Harmful Drug Use

United States
Research Foundation for Mental Hygiene, Inc.

Active, not recruiting

Meditation and Kundalini Yoga for Heightened Anxiety Related to COVID-19

Generalized Anxiety | Health Anxiety

United States
Research Foundation for Mental Hygiene, Inc.

Completed

Reducing Unsafe Alcohol Use in HIV-Positive Individuals

Alcohol Abuse

United States
Research Foundation for Mental Hygiene, Inc.

Completed

HealthCall-S: A Pilot Study Targeting Concurrent Non-injection Drug Use and Alcohol in HIV Primary Care Clinics

Alcohol or Other Drugs Use

United States
Research Foundation for Mental Hygiene, Inc.

Active, not recruiting

Training Church Leaders in Mental Health First Aid

Stigma

United States
Research Foundation for Mental Hygiene, Inc.

Completed

Reducing Stigma Towards Depression Among Adolescents

Stigma, Social

United States
Research Foundation for Mental Hygiene, Inc.

Terminated

Combined Treatment of Prolonged Exposure and Pramipexole for Posttraumatic Stress Disorder and Depression

PTSD | MDD

United States
Research Foundation for Mental Hygiene, Inc.

Completed

Behavioral Activation/Armodafinil to Treat Fatigue in HIV/AIDS

Fatigue | Hiv | Goals

United States

Clinical Trials Sponsored by Panthera Dental Inc.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mauritania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations